Johnson & Johnson’s DePuy Synthes has acquired Sentio, which makes nerve localization technology for spine surgery, for an undisclosed amount.
Nerve localization technologies help physicians avoid injuring nerves while performing spine procedures. Most systems use several needle electrodes in the patient’s limbs to locate motor neurons in the spine. They then generate signals that a neuromonitoring specialist interprets, guiding the surgeon.
However, neurologic complications persist in spite of these nerve localization systems, DePuy said in a statement. These complications, including pain or weakness in the hip or leg, result from the bruising or stretching of nerves near the surgical area. Temporary complications affect 9.4% of patients, while permanent complications are reported in 2.5% of patients, a study showed.
Enter Sentio, which uses adhesive sensors placed on the skin at relevant muscle groups and gives the surgeon feedback in real time. Sentio’s system does not require a specialist to set it up or to interpret signals.
“With Sentio’s nerve localization technology, DePuy Synthes will strengthen its spine portfolio in decompression procedures as well as lateral surgery, and build a platform for future innovation in minimally invasive surgery,” said Ciro Römer, DePuy Synthes chairman, in the statement. “The surgeon-driven approach will also help us reach more customers operating in an ambulatory surgery setting. This acquisition underscores our commitment to investing in differentiated technologies that help us reach more customers and patients around the world.”
Sentio initially focused on a narrow market in southeast Michigan, but DePuy plans to use its network to roll the system out globally.
By Amirah Al Idrus
Source: Fierce Biotech
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
